NCT04417465: First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors

NCT04417465
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated brain or meningeal metastases – see trial for details; Patients treated with anti-programmed cell death protein-1 (PD-1)/anti-programmed cell death protein-ligand 1(PD-L1) targeting or other immunostimulatory agents in the past
https://ClinicalTrials.gov/show/NCT04417465

Comments are closed.

Up ↑